Viral vectors having enhanced effectiveness with reduced virulence

• US 6,846,652 B2
• Filed: 06/22/2001
• Issued: 01/25/2005
• Est. Priority Date: 05/27/1999
• Status: Expired due to Fees

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Brandt, Teresa A., Jacobs, Bertram
• Primary Examiner(s): SCHEINER, LAURIE A
• Application Number:
  US09/887,295
• Publication Number:
  US 20020110565A1
• Time in Patent Office: 1,313 Days
• Field of Search: 435/69.1, 435/91.41, 435/320.1, 435/69.3, 435/455, 435/456, 536/23.72, 536/23.1, 424/184.1, 424/204.1, 424/232.1, 424/93.1, 424/93.2, 424/93.6
• US Class Current: 435/69.3
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/285 Vaccinia virus or variola virus
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector

Abstract

The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising the recombinant vaccinia virus are also provided.

Claims

1. An expression vector comprising:

a recombinant vaccinia virus having an E3L gene

(a) having a deletion of the region encoding amino acids 1-54 of the E3L gene product and

(b) encoding a protein that binds dsRNA; and

exogenous DNA and regulatory elements operably linked thereto.

2. A composition comprising the vector of claim 1 and a carrier.

3. A method of making a recombinant gene product comprising:

subjecting an expression vector comprising;

a recombinant vaccinia virus having an E3L gene

(a) having a deletion of the region encoding amino acids 1-54 of the E3L gene product and

(b) encoding a protein that binds dsRNA; and

exogenous DNA that encodes said recombinant gene product regulatory elements operably linked thereto,

to conditions whereby said recombinant gene product is expressed.

4. The method of claim 3 further comprising recovering said recombinant gene product.

5. The method of claim 3 wherein said recombinant gene product is an antigen.